Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
2 hedge funds and large institutions have $5K invested in Global X China Biotech Innovation ETF in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
33% less funds holding
Funds holding: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
99% less capital invested
Capital invested by funds: $360K → $5K (-$355K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$190K |
| 2 |
Jane Street
New York
|
-$167K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BBPWM
1
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $3K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $2K | +$2.04K | +202 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$190K | -16,484 | Closed |
|
|
4
Jane Street
New York
| – | -$167K | -14,549 | Closed |
|
CHB Hedge Fund Activity: Q2 2022 in Review
2 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q2 2022, worth a combined $5K — down 99% from $360K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CHB and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $2.04K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $190K sold.
- 2 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q2 2022, down from 3 in Q1 2022.
- Funds reported $5K of Global X China Biotech Innovation ETF stock for Q2 2022, down 99% quarter-over-quarter.
- 1 fund opened new Global X China Biotech Innovation ETF positions in Q2 2022 and 2 closed out, a net change of -1 holder.
- The largest Global X China Biotech Innovation ETF buyer in Q2 2022 was UBS Group, an estimated $2.04K added.
- The largest Global X China Biotech Innovation ETF seller in Q2 2022 was Susquehanna International Group, an estimated $190K sold.
Based on aggregated 13F filings for Q2 2022.